Allurion Connected News Today

Allurion Technologies, Inc. , a company dedicated to ending obesity, today announced that it will be participating in two upcoming investor conferences: Jefferies Global Healthcare...

Generated quarter-over-quarter revenue growth and continued growth in procedural volume, while substantially reducing cash burn Company to report full first quarter 2024 financial results on May...

Virtual Care Suite is now available to license in the United States for providers offering GLP-1 and other anti-obesity medication therapy, bariatric surgery, and weight loss devices US product...

Allurion Technologies, Inc. , a company dedicated to ending obesity, today announced that it will be participating in the 34th Annual Oppenheimer Healthcare MedTech & Services Conference, taking...

Allurion Technologies, Inc. , a company dedicated to ending obesity, today announced the appointment of its newest board member and Audit Committee Chair, Milena Alberti-Perez, effective as of March...

Allurion Technologies, Inc. , a company dedicated to ending obesity, today announced the appointment of Brendan Gibbons as its new Chief Legal Officer and corporate secretary. Brendan joins...

Allurion Program is the latest innovation in the NHS’s war against obesity ...

Allurion Program led to resolution of type 2 diabetes, hypertension, and obstructive sleep apnea in just 4 months in over half of the patients treated Results improved with addition of oral GLP-1...

NATICK - Allurion Technologies, Inc. , a company dedicated to ending obesity, today announced preliminary unaudited results for the fourth quarter and full year 2023. The Company also issued its...

Generated substantial procedure growth in 2023 driven by best-in-class efficacy of balloon program; prioritizing key investments in strategic markets and digital innovations ahead of FDA milestones ...